a pharmaceutical composition comprising dihomo gamma linolenic acid (DGLA) or a derivative thereof in the manufacture of a medicament for treating a skin disease or disorder, wherein the composition comprises at least about 80% DGLA by weight of total fatty acids and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid. In a further aspect, there is disclosed use of a pharmaceutical composition comprising dihomo gamma linolenic acid (DGLA) or a derivative thereof encapsulated in a capsule shell comprising gelatin, d-sorbitol and 1,4-sorbitan sugar alcohols in the manufacture of a medicament for increasing skin DGLA levels or treating a skin disease, wherein the composition comprises at least about 80% DGLA by weight of total fatty acids and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid. In yet another aspect, there is disclosed a pharmaceutical composition comprising 200 mg to about 1 g of a composition encapsulated in a capsule shell, wherein the composition comprises not less than 95% by weight dihomo gamma linolenic acid (DGLA), not more than 5% of any individual fatty acid selected from 20:2ω6, 20:3ω3, 20:4ω6, 20:4ω3 and 20:5ω3, and not more than 2% by weight unidentified related substances, wherein the composition comprises at least about 80% DGLA by weight of total fatty acids and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid. In a further example, there is disclosed use of a pharmaceutical composition comprising at least about 80% dihomo gamma linolenic acid (DGLA) or a derivative thereof by weight of total fatty acids in the composition, and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid, in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof, wherein the disease or disorder is selected from: skin disorders and diseases, including acne vulgaris, acne rosacea, atopic dermatitis, psoriasis, pruritus/itch, radiation protection, dry skin, smooth skin, healthy skin, anti-aging, and photoprotection; urinary disorders and diseases including bladder cancer, cystocele, hematuria, interstitial cystitis, neurogenic bladder, Peyronie's disease, prostate disease, incontinence, urinary tract infection and vasicoureteral reflux; renal disease and disorders including kidney failure, acute kidney injury, chronic kidney disease, and polycystic kidney disease; rheumatic disease including ankylosing spondylitis, fibromyalgia, gout, infectious arthritis, lupus, osteoarthritis, polymyalgia rheumatic, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sclerodoma; respiratory disorders including inflammatory lung disease, respiratory tract infections, pleural cavity disease, pulmonary vascular disease, pneumonia, pulmonary embolism, and lung cancer; and cardiovascular disorders including acute cardiac ischemic events, acute myocardial infarction, angina, arrhythmia, atrial fibrulation, atherosclerosis, arterial fibrillation, cardiac insufficiency, cardiovascular disease, chronic heart failure, chronic stable angina, congestive heart failure, coronary artery disease, coronary heart disease, deep vein thrombosis, diabetes, diabetes mellitus, diabetic neuropathy, diastolic dysfunction in subjects with diabetes mellitus, edema, essential hypertension, eventual pulmonary embolism, fatty liver disease, heart disease, heart failure, homozygous familial hypercholesterolemia (HoFH), homozygous familial

sitosterolemia, hypercholesterolemia, hyperlipidemia, hypertension, hypertriglyceridemia, metabolic syndrome, mixed dyslipidemia, moderate to mild heart failure, myocardial infarction, obesity management, paroxysmal atrial/arterial fibrillation/fibrulation/flutter, paroxysmal supraventricular tachycardias (PSVT), particularly severe or rapid onset edema, platelet aggregation, primary hypercholesterolemia, primary hyperlipidemia, pulmonary arterial hypertension, pulmonary hypertension, recurrent hemodynamically unstable ventricular tachycardia (VT), recurrent ventricular arrhythmias, recurrent ventricular fibrillation (VF), ruptured aneurysm, sitisterolemia, stroke, supraventricular tachycardia, symptomatic atrial fibrillation/flutter, tachycardia, type-II diabetes, vascular disease, venous thromboembolism, and ventricular arrhythmias. In yet another aspect, there is disclosed a pharmaceutical composition as disclosed herein for use in treating of skin disorders and diseases, including acne vulgaris, acne rosacea, atopic dermatitis, psoriasis, pruritus/itch, radiation protection, dry skin, smooth skin, healthy skin, anti-aging, and photoprotection; urinary disorders and diseases including bladder cancer, cystocele, hematuria, interstitial cystitis, neurogenic bladder, Peyronie's disease, prostate disease, incontinence, urinary tract infection and vasicoureteral reflux; renal disease and disorders including kidney failure, acute kidney injury, chronic kidney disease, and polycystic kidney disease; rheumatic disease including ankylosing spondylitis, fibromyalgia, gout, infectious arthritis, lupus, osteoarthritis, polymyalgia rheumatic, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sclerodoma; respiratory disorders including inflammatory lung disease, respiratory tract infections, pleural cavity disease, pulmonary vascular disease, pneumonia, pulmonary embolism, and lung cancer; and cardiovascular disorders including acute cardiac ischemic events, acute myocardial infarction, angina, arrhythmia, atrial fibrulation, atherosclerosis, arterial fibrillation, cardiac insufficiency, cardiovascular disease, chronic heart failure, chronic stable angina, congestive heart failure, coronary artery disease, coronary heart disease, deep vein thrombosis, diabetes, diabetes mellitus, diabetic neuropathy, diastolic dysfunction in subjects with diabetes mellitus, edema, essential hypertension, eventual pulmonary embolism, fatty liver disease, heart disease, heart failure, homozygous familial hypercholesterolemia (HoFH), homozygous familial sitosterolemia, hypercholesterolemia, hyperlipidemia, hypertension, hypertriglyceridemia, metabolic syndrome, mixed dyslipidemia, moderate to mild heart failure, myocardial infarction, obesity management, paroxysmal atrial/arterial fibrillation/fibrulation/flutter, paroxysmal supraventricular tachycardias (PSVT), particularly severe or rapid onset edema, platelet aggregation, primary hypercholesterolemia, primary hyperlipidemia, pulmonary arterial hypertension, pulmonary hypertension, recurrent hemodynamically unstable ventricular tachycardia (VT), recurrent ventricular arrhythmias, recurrent ventricular fibrillation (VF), ruptured aneurysm, sitisterolemia, stroke, supraventricular tachycardia, symptomatic atrial fibrillation/flutter, tachycardia, type-II diabetes, vascular disease, venous thromboembolism, and ventricular arrhythmias. In another aspect, the present invention refers to use of a pharmaceutical composition comprising at least about 80% dihomo gamma linolenic acid (DGLA) or a derivative thereof by weight of total fatty acids in the composition, and at least one other fatty acid selected from the group

consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid, in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof, wherein the disease or disorder is selected from: skin disorders and diseases, including acne vulgaris, acne rosacea, atopic dermatitis, psoriasis, pruritus/itch, and radiation protection; urinary disorders and diseases including bladder cancer, cystocele, hematuria, interstitial cystitis, neurogenic bladder, Peyronie's disease, prostate disease, incontinence, urinary tract infection and vasicoureteral reflux; renal disease and disorders including kidney failure, acute kidney injury, chronic kidney disease, and polycystic kidney disease; rheumatic disease including ankylosing spondylitis, fibromyalgia, gout, infectious arthritis, lupus, osteoarthritis, polymyalgia rheumatic, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sclerodoma; respiratory disorders including inflammatory lung disease, respiratory tract infections, pleural cavity disease, pulmonary vascular disease, pneumonia, pulmonary embolism, and lung cancer; and cardiovascular disorders including acute cardiac ischemic events, acute myocardial infarction, angina, arrhythmia, atrial fibrulation, atherosclerosis, arterial fibrillation, cardiac insufficiency, cardiovascular disease, chronic heart failure, chronic stable angina, congestive heart failure, coronary artery disease, coronary heart disease, deep vein thrombosis, diabetes, diabetes mellitus, diabetic neuropathy, diastolic dysfunction in subjects with diabetes mellitus, edema, essential hypertension, eventual pulmonary embolism, fatty liver disease, heart disease, heart failure, homozygous familial hypercholesterolemia (HoFH), homozygous familial sitosterolemia, hypercholesterolemia, hyperlipidemia, hypertension, hypertriglyceridemia, metabolic syndrome, mixed dyslipidemia, moderate to mild heart failure, myocardial infarction, obesity management, paroxysmal atrial/arterial fibrillation/fibrulation/flutter, paroxysmal supraventricular tachycardias (PSVT), particularly severe or rapid onset edema, platelet aggregation, primary hypercholesterolemia, primary hyperlipidemia, pulmonary arterial hypertension, pulmonary hypertension, recurrent hemodynamically unstable ventricular tachycardia (VT), recurrent ventricular arrhythmias, recurrent ventricular fibrillation (VF), ruptured aneurysm, sitisterolemia, stroke, supraventricular tachycardia, symptomatic atrial fibrillation/flutter, tachycardia, type-II diabetes, vascular disease, venous thromboembolism, and ventricular arrhythmias.

[0028] In one example, there is disclosed a pharmaceutical composition comprising DGLA. In one example, the composition is encapsulated in a capsule shell. In one example, there is disclosed a pharmaceutical composition comprising DGLA encapsulated in a capsule shell comprising gelatin, d-sorbitol and 1,4-sorbitan sugar alcohols. In one example, about 500 mg to about 1 g of DGLA or a derivative thereof is encapsulated in the capsule shell.

8. The use of claim 7 wherein the composition is formulated to provide about 0.2 g to about 8 g of DGLA per day.

9. The use of claim 6 wherein the composition is formulated to be administered in 1 to 8 capsules per day to the subject.

10. The use of claim 9 wherein each capsule comprises about 200 mg to about 1 g of DGLA.

11. Use of a pharmaceutical composition comprising dihomo gamma linolenic acid (DGLA) or a derivative thereof encapsulated in a capsule shell comprising gelatin, d-sorbitol and 1,4-sorbitan sugar alcohols in the manufacture of a medicament for increasing skin DGLA levels or treating a skin disease, wherein the composition comprises at least about 80% DGLA by weight of total fatty acids and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid.

12. A pharmaceutical composition comprising 200 mg to about 1 g of a composition encapsulated in a capsule shell, wherein the composition comprises not less than 95% by weight dihomo gamma linolenic acid (DGLA), not more than 5% of any individual fatty acid selected from 20:2ω6, 20:3ω3, 20:4ω6, 20:4ω3 and 20:5ω3, and not more than 2% by weight unidentified related substances, wherein the composition comprises at least about 80% DGLA by weight of total fatty acids and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid.

13. Use of a pharmaceutical composition comprising at least about 80% dihomo gamma linolenic acid (DGLA) or a derivative thereof by weight of total fatty acids in the composition, and at least one other fatty acid selected from the group consisting of eicosatetraenoic acid, oleic acid, linoleic acid, and eicosadienoic acid, in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof, wherein the disease or disorder is selected from: skin disorders and diseases, including acne vulgaris, acne rosacea, atopic dermatitis, psoriasis, pruritus/itch, and radiation protection; urinary disorders and diseases including bladder cancer, cystocele, hematuria, interstitial cystitis, neurogenic bladder, Peyronie's disease, prostate disease, incontinence, urinary tract infection and vasicoureteral reflux; renal disease and disorders including kidney failure, acute kidney injury, chronic kidney disease, and polycystic kidney disease; rheumatic disease including ankylosing spondylitis, fibromyalgia, gout, infectious arthritis, lupus, osteoarthritis, polymyalgia